Education
About Us
Working with TipRanks
Follow Us
Duality Biotherapeutics, Inc. (HK:9606)
:9606
Top Page
Duality Biotherapeutics, Inc.
(9606)
Rating:51Neutral
Price Target:
HK$344.00
▲(9.00% Upside)
Duality Biotherapeutics, Inc. (9606) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$27.78B
Dividend YieldN/A
Average Volume (3M)239.74K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees170
SectorHealthcare
Sector Strength51
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding88,036,260
10 Day Avg. Volume334,218
30 Day Avg. Volume239,737
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$355.53Price Target Upside12.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Duality Biotherapeutics, Inc. Business Overview & Revenue Model
Company DescriptionDuality Biotherapeutics, Inc. operates as a clinical stage company. It focuses on the development of next generation antibody-drug conjugate therapeutics and duality immune toxin antibody conjugate therapeutic. The company was founded by Zhu Zhong Yuan on July 3, 2019 and is headquartered in Shanghai, China.
How the Company Makes MoneyDuality Biotherapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, which often involve milestone payments and royalties on sales of products developed through these partnerships. Additionally, the company may receive funding from government grants and research institutions in support of its clinical trials and development programs. The commercialization of its proprietary therapeutics once they receive regulatory approval will also contribute to revenue through direct sales and licensing agreements. Furthermore, Duality's ability to attract investments from venture capital and private equity firms plays a crucial role in funding its research and development efforts, thereby indirectly supporting its revenue generation capacity.
Duality Biotherapeutics, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Duality Biotherapeutics, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$10.14B | 11.36 | 8.62% | 3.93% | 2.32% | -14.41% | |
69 Neutral | HK$12.37B | 258.75 | 1.33% | 0.66% | ― | ― | |
63 Neutral | HK$7.67B | 20.61 | 14.86% | 1.26% | 16.41% | 32.97% | |
57 Neutral | HK$1.57B | ― | -8.64% | ― | -20.99% | 45.74% | |
54 Neutral | HK$12.31B | 19.92 | 35.80% | ― | 59.70% | 239.97% | |
51 Neutral | $7.85B | -0.21 | -41.41% | 2.22% | 22.81% | -2.01% | |
51 Neutral | HK$27.78B | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
HK:9606
Duality Biotherapeutics, Inc.
315.60
128.40
68.59%
HK:2142
HBM Holdings Ltd.
14.72
13.58
1191.23%
HK:2216
Broncus Holding Corp.
2.97
2.44
460.38%
HK:2273
Gushengtang Holdings Limited
32.50
-4.17
-11.37%
HK:6699
Angelalign Technology Inc.
72.45
19.56
36.98%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
7.65
2.62
52.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.